Filters
Patients with functional dyspepsia (FD) may benefit from transcutaneous neuromodulation (TN) treatment, which can significantly improve symptoms and quality of life, according to a study.
Long-term monthly treatment with givosiran has good tolerability and offers continuous improvements to patients with acute hepatic porphyria (AHP), results of the phase III ENVISION trial have shown.
Individuals with intracranial atherosclerosis disease (ICAD) have a heightened risk of cognitive impairment and dementia, according to the results of a systematic review and meta-analysis.
Twelve-month treatment with zoledronate significantly increases bone mineral density (BMD) Z-scores without affecting growth in nonambulant children with cerebral palsy (CP), reports a study. However, side effects of the first dose are common.
Metformin treatment discontinuation has been found to lead to increased incidence of dementia among older adults, and this association cannot be explained by changes in glucose control or insulin use.
Chronic hepatitis B virus (HBV) infection appears to put Chinese adults at higher risk of intracerebral haemorrhage but not other stroke subtypes, as reported in a study.
Strawberries can potentially contribute to the prevention of dementia, with a small study suggesting that supplementation with whole-fruit strawberry powder helps improve memory in middle-aged adults.
A post hoc analysis of the CHANCE-2 randomized controlled trial (RCT) demonstrates that ticagrelor-aspirin combination therapy is associated with a significantly lower risk of new stroke within 90 days vs the clopidogrel-aspirin combination in Chinese CYP2C19 loss‐of‐function allele carriers with minor stroke or transient ischaemic attack (TIA) without intracranial artery stenosis (ICAS).
Painful diabetic peripheral neuropathy (pDPN) is the most common chronic complication of diabetes mellitus resulting from nerve damage in patients’ lower limbs.
A double-blind, placebo-controlled, randomized clinical trial reports significant improvement in agitation with brexpiprazole vs placebo among patients with Alzheimer’s dementia.
